Internship
Genesis Therapeutics
51-200 employees
AI-driven drug discovery for pharmaceuticals
No salary listed
Burlingame, CA, USA
Upload your resume to see how it matches 2 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
- A strong software engineer who will write code quickly and uphold our code quality standards
- A deep thinker who reasons from first principles over pattern matching
- Interested in learning about biochemistry and the drug development process
- Build and expand on tools for visualizing molecules and proteins, analyzing machine learning models, and managing complex chemical workflows
- Work closely with machine learning engineers and medicinal chemists to develop and productionize new computational methods for molecular property prediction
- Help scale our data infrastructure to handle billions of datapoints and thousands of parallel deep learning and molecular dynamics jobs
Genesis Therapeutics accelerates the development of new medicines by using artificial intelligence in drug discovery. The company combines 3D spatial graph modeling and molecular simulation to identify potential drug candidates and explore new chemical spaces. Unlike its competitors, Genesis focuses on strategic partnerships with other biotech and pharmaceutical companies, generating revenue through upfront payments and future earnings based on drug success. The goal is to transform drug discovery and develop critical new medicines.
Company Size
51-200
Company Stage
Series B
Total Funding
$280.1M
Headquarters
Burlingame, California
Founded
2019
Simplify's Take
What believers are saying
- Partnership with NVIDIA enhances AI capabilities for drug discovery.
- Strategic collaborations expand therapeutic pipeline and address unmet medical needs.
- Recognition as a 'Fierce 15' company boosts industry credibility.
What critics are saying
- High competition from AI-driven drug discovery companies like Insilico Medicine.
- Over-reliance on partnerships could lead to financial instability.
- Rapid AI advancements may render current models obsolete without continuous innovation.
What makes Genesis Therapeutics unique
- Genesis uses 3D spatial graph modeling for novel drug candidate generation.
- The GEMS platform leverages physics-inspired AI for drug discovery.
- Genesis collaborates with major pharma companies like Eli Lilly and Gilead.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Competitive salary
Equity
Medical, dental, & vision insurance
401(k) program
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 0%2 year growth
↑ 1%Incyte is sticking to its strategy this year of finding "early-stage, exotic stuff" - paying Genesis Therapeutics $30 million upfront to use the biotech's artificial intelligence platform to develop small molecule medicines against undisclosed targets.
Nvidia’s venture arm, NVentures, has increased its investment in AI drug discovery firm Genesis Therapeutics. Genesis, founded by Evan Feinberg, has raised over $300 million, including a $200 million Series B in 2023. The collaboration aims to enhance Genesis' AI platform, GEMS, for drug discovery. Genesis is also working with Gilead, Eli Lilly, and Genentech on various projects. The company plans to expand its workforce beyond its current 80 employees.
Genesis Therapeutics receives equity investment from NVIDIA.
Genesis Therapeutics has partnered with NVIDIA to enhance its AI platform, GEMS, for drug discovery. This collaboration is supported by additional funding from NVentures, NVIDIA's venture capital arm, following its participation in Genesis' $200 million Series B financing in August 2023. The partnership aims to optimize computational methods like equivariant neural networks to analyze complex 3D molecular structures, targeting diseases with high unmet needs and previously undruggable targets.
Gilead Sciences (GILD) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.